Abstract
The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.
Original language | English (US) |
---|---|
Pages (from-to) | 85-91 |
Number of pages | 7 |
Journal | Cancer Chemotherapy and Pharmacology |
Volume | 72 |
Issue number | 1 |
DOIs | |
State | Published - Jul 2013 |
Keywords
- Docetaxel
- Oxaliplatin
- Oxaliplatin and Docetaxel
- Phase I
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Pharmacology
- Pharmacology (medical)
- Toxicology